FDA approves test to diagnose MPNs

Print Friendly, PDF & Email


Essential thrombocythemia
The US Food and Drug Administration (FDA) has cleared use of QIAGEN’s ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) for the diagnosis of all myeloproliferative neoplasms (MPNs). The ipsogen JAK2 assay is a qualitative, in vitro diagnostic test designed to detect the JAK2 V617F/G1849T allele in genomic DNA extracted from... [Read Article]
Print Friendly, PDF & Email

Allo-HSCT leads to long-term survival in MF

Print Friendly, PDF & Email


Attendees at ASH 2017
Photo courtesy of ASH
© Todd Buchanan 2017
One of the largest single-center studies of fludarabine/melphalan-based allogeneic hematopoietic stem cell transplant (allo-HSCT) for patients with myelofibrosis (MF) shows excellent overall survival (OS) with a low risk of relapse, according to investigators. Allo-HSCT is the only potential curative treatment modality... [Read Article]
Print Friendly, PDF & Email

CHMP recommends generic drug for ET

Print Friendly, PDF & Email


Micrograph showing ET
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Anagrelide Mylan. The product is intended to reduce elevated platelet counts in at-risk patients with essential thrombocythemia (ET). Anagrelide Mylan is a generic of Xagrid (0.5 mg hard capsules),... [Read Article]
Print Friendly, PDF & Email

Plek2 may be therapeutic target in MPNs

Print Friendly, PDF & Email


Lab mouse
New research suggests plecktrin-2 (Plek2) may be a therapeutic target for myeloproliferative neoplasms (MPNs). Plek2 was previously shown to be involved in red blood cell production. Now, researchers have found Plek2 is upregulated in patients with JAK2V617F-positive MPNs. And loss of Plek2 ameliorated JAK2V617F-induced myeloproliferative phenotypes in a mouse model. Peng... [Read Article]
Print Friendly, PDF & Email

FDA approves first treatment for ECD

Print Friendly, PDF & Email


Micrograph showing ECD
Image from Wikipedia
The US Food and Drug Administration (FDA) has expanded the approved use of vemurafenib (Zelboraf) to include the treatment of adults who have Erdheim-Chester disease (ECD) with BRAF V600 mutation. Vemurafenib is a kinase inhibitor designed to inhibit some mutated forms of BRAF. The drug was already approved... [Read Article]
Print Friendly, PDF & Email

NCCN releases new guidelines for patients with MPNs

Print Friendly, PDF & Email


Polycythemia vera
Image courtesy of AFIP
The National Comprehensive Cancer Network® (NCCN) has released new guidelines for patients with myeloproliferative neoplasms (MPNs). The guidelines include information on the diagnosis and treatment of polycythemia vera, essential thrombocythemia, and myelofibrosis. NCCN Guidelines for Patients® are written in plain language and include tools such as suggested questions... [Read Article]
Print Friendly, PDF & Email